亿帆医药
(002019)
| 流通市值：106.53亿 | | | 总市值：154.00亿 |
| 流通股本：8.41亿 | | | 总股本：12.16亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,922,709,366.04 | 2,635,110,083.18 | 1,326,616,043.2 | 5,159,823,227.64 |
| 营业收入 | 3,922,709,366.04 | 2,635,110,083.18 | 1,326,616,043.2 | 5,159,823,227.64 |
| 二、营业总成本 | 3,507,090,512.56 | 2,316,453,207.97 | 1,200,723,203.71 | 4,758,180,864.67 |
| 营业成本 | 2,046,852,839.24 | 1,355,113,404.41 | 711,260,943.92 | 2,713,055,053.04 |
| 税金及附加 | 38,283,518.03 | 26,816,307.83 | 16,423,339 | 50,441,891.05 |
| 销售费用 | 911,396,543.31 | 620,586,202.68 | 313,628,723.36 | 1,220,889,028.37 |
| 管理费用 | 284,315,519.78 | 180,754,339.09 | 87,010,401.46 | 408,136,226.79 |
| 研发费用 | 191,866,180.76 | 118,627,834.42 | 63,503,366.31 | 291,966,914.3 |
| 财务费用 | 34,375,911.44 | 14,555,119.54 | 8,896,429.66 | 73,691,751.12 |
| 其中:利息费用 | 42,365,805.07 | 25,822,154.1 | 13,375,730.41 | 69,100,599.7 |
| 其中:利息收入 | 7,897,184.85 | 5,452,211.74 | 3,153,053.7 | 8,120,841.77 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -250,625.62 | -459,827.92 | - | - |
| 加:投资收益 | -22,725,516.58 | -14,370,446.64 | -7,259,252.11 | -14,164,575.31 |
| 资产处置收益 | 10,132,477.36 | 3,858,234.66 | -105,871.91 | 30,145,653.64 |
| 资产减值损失(新) | -16,001,135.53 | -11,333,286.25 | -4,880,770.28 | -105,335,584.57 |
| 信用减值损失(新) | -28,310,577.33 | -23,146,737.3 | -18,267,116.66 | -59,555,773.08 |
| 其他收益 | 77,243,373.06 | 69,741,135.46 | 61,681,911.99 | 129,078,098.9 |
| 四、营业利润 | 435,706,848.84 | 342,945,947.22 | 157,061,740.52 | 381,810,182.55 |
| 加:营业外收入 | 2,831,097.27 | 2,571,952.61 | 106,799.17 | 14,758,703.59 |
| 减:营业外支出 | 3,726,977.38 | 1,193,751.91 | 485,840.78 | 7,911,933.86 |
| 五、利润总额 | 434,810,968.73 | 344,324,147.92 | 156,682,698.91 | 388,656,952.28 |
| 减:所得税费用 | 74,558,949.74 | 60,166,012.1 | 18,453,067.29 | 65,035,239.66 |
| 六、净利润 | 360,252,018.99 | 284,158,135.82 | 138,229,631.62 | 323,621,712.62 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 360,252,018.99 | 284,158,135.82 | 138,229,631.62 | 323,621,712.62 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 387,786,703.89 | 303,651,052.46 | 153,161,633.89 | 385,967,572.95 |
| 少数股东损益 | -27,534,684.9 | -19,492,916.64 | -14,932,002.27 | -62,345,860.33 |
| 扣除非经常损益后的净利润 | 315,399,316.03 | 237,210,048.08 | 95,369,685.69 | 248,094,095.26 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.32 | 0.25 | 0.13 | 0.32 |
| (二)稀释每股收益 | 0.32 | 0.25 | 0.13 | 0.32 |
| 八、其他综合收益 | 40,735,013.03 | 61,055,565.28 | 20,675,101.78 | -25,329,608.54 |
| 归属于母公司股东的其他综合收益 | 40,570,592.37 | 61,155,138.74 | 20,234,459.93 | -25,621,468.38 |
| 九、综合收益总额 | 400,987,032.02 | 345,213,701.1 | 158,904,733.4 | 298,292,104.08 |
| 归属于母公司股东的综合收益总额 | 428,357,296.26 | 364,806,191.2 | 173,396,093.82 | 360,346,104.57 |
| 归属于少数股东的综合收益总额 | -27,370,264.24 | -19,592,490.1 | -14,491,360.42 | -62,054,000.49 |
| 公告日期 | 2025-10-31 | 2025-08-15 | 2025-04-30 | 2025-04-28 |
| 审计意见(境内) | | | | 标准无保留意见 |